Recent News

• 03.03.2025 - Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
• 02.18.2025 - Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
• 02.10.2025 - Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
• 02.05.2025 - Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
• 02.05.2025 - Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
• 01.27.2025 - US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
• 12.30.2024 - Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
• 12.04.2024 - 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug

Recent Filings

• 03.03.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.18.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.05.2025 - EX-99.1 EX-99.1
• 01.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.27.2025 - EX-99.1 EX-99.1
• 12.30.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]